ALNY stock sentiment todayAlnylam Pharmaceuticals, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
ALNY
Alnylam Pharmaceuticals, Inc.The RNAi pioneer is transitioning from a high-burn biotech to a commercial powerhouse following the massive success of the HELIOS-B trial for Amvuttra.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ALNY. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from 'R&D curiosity' to 'cardiology blockbuster.' Recent clinical success in ATTR-CM has analysts projecting Alnylam as a prime M&A target for Big Pharma looking to bolster cardiovascular pipelines.
- ·Amvuttra HELIOS-B phase 3 data success
- ·Speculation of a buyout by players like Novartis or Roche
- ·Expansion into high-prevalence indications like hypertension
Financial
Revenue growth is accelerating (roughly 30%+ YoY) driven by the TTR franchise. While GAAP net losses persist due to heavy R&D, the path to profitability is clear as Amvuttra targets a multi-billion dollar market in ATTR-CM.
- ·Cash and equivalents over $2.4B providing multi-year runway
- ·Product sales growth led by Amvuttra and Onpattro
- ·Significant milestone payments from partners like Roche and Regeneron
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $399K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Medicare price negotiation (IRA) impact on orphan drugs
- ·Heavy competition from Pfizer’s Vyndaqel/Vyndamax
- ·Execution risk in scaling the global cardiology sales force
Peer temperature
How direct competitors stack up against ALNY right now.
- NEUTRALIONSIonis Pharmaceuticals
COLDER — trailing in the ATTR-CM race with Wainua compared to Alnylam’s superior HELIOS-B clinical profile.
See full analysis → - COLDPFEPfizer
COLDER — facing massive patent cliffs and declining COVID revenue, despite currently leading the ATTR market with Vyndaqel.
See full analysis → - HOTVRTXVertex Pharmaceuticals
HOTTER — offers a more diversified commercial portfolio and higher net margins with a similar 'monopoly' status in cystic fibrosis.
See full analysis →
- ALNY-33.1%
- IONS-2.5%
- PFE+7.0%
- VRTX+6.9%
Analyst price target
Consensus average of 23 analysts · median 325.20
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.